Juno Therapeutics, Inc. (NASDAQ:JUNO) was downgraded by Vetr from a “hold” rating to a “sell” rating in a report issued on Monday, August 7th. They currently have a $28.47 price target on the biopharmaceutical company’s stock. Vetr‘s price target would suggest a potential upside of 5.48% from the company’s previous close.
Several other equities analysts have also issued reports on the company. Wedbush reaffirmed a “neutral” rating and set a $24.00 price target on shares of Juno Therapeutics in a research note on Friday, May 5th. BidaskClub raised Juno Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, June 27th. Morgan Stanley cut their price target on Juno Therapeutics from $27.00 to $26.00 and set an “equal weight” rating on the stock in a research note on Monday, May 8th. FBR & Co reaffirmed a “hold” rating on shares of Juno Therapeutics in a research note on Thursday, May 18th. Finally, Zacks Investment Research lowered Juno Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 2nd. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have issued a buy rating to the stock. Juno Therapeutics presently has an average rating of “Hold” and an average target price of $30.63.
Juno Therapeutics (JUNO) traded down 0.26% on Monday, reaching $26.99. The company had a trading volume of 788,677 shares. The company’s market capitalization is $2.83 billion. The company’s 50 day moving average price is $28.75 and its 200-day moving average price is $24.87. Juno Therapeutics has a 12 month low of $17.52 and a 12 month high of $34.35.
Juno Therapeutics (NASDAQ:JUNO) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by $0.24. Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The firm had revenue of $21.30 million for the quarter, compared to analyst estimates of $15.59 million. During the same period last year, the company earned ($0.64) EPS. The company’s revenue was down 22.8% compared to the same quarter last year. On average, equities analysts predict that Juno Therapeutics will post ($3.13) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Vetr Inc. Downgrades Juno Therapeutics, Inc. (JUNO) to Sell” was reported by BNB Daily and is the sole property of of BNB Daily. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.baseball-news-blog.com/2017/08/19/juno-therapeutics-inc-juno-stock-rating-lowered-by-vetr-inc-updated.html.
In other Juno Therapeutics news, major shareholder Douglas K. Bratton sold 8,000,000 shares of the stock in a transaction dated Thursday, July 13th. The stock was sold at an average price of $27.00, for a total value of $216,000,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard Klausner sold 12,000 shares of the stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $30.34, for a total value of $364,080.00. Following the completion of the sale, the director now owns 788,985 shares of the company’s stock, valued at $23,937,804.90. The disclosure for this sale can be found here. Insiders sold 8,053,500 shares of company stock valued at $217,594,440 in the last quarter. 15.26% of the stock is currently owned by corporate insiders.
Several large investors have recently made changes to their positions in JUNO. Baillie Gifford & Co. increased its stake in shares of Juno Therapeutics by 1.2% in the first quarter. Baillie Gifford & Co. now owns 11,197,863 shares of the biopharmaceutical company’s stock valued at $248,481,000 after buying an additional 135,908 shares during the period. Vanguard Group Inc. increased its stake in shares of Juno Therapeutics by 2.1% in the second quarter. Vanguard Group Inc. now owns 6,285,676 shares of the biopharmaceutical company’s stock valued at $187,879,000 after buying an additional 131,864 shares during the period. BlackRock Inc. increased its stake in shares of Juno Therapeutics by 2.6% in the second quarter. BlackRock Inc. now owns 4,294,296 shares of the biopharmaceutical company’s stock valued at $128,357,000 after buying an additional 110,503 shares during the period. State Street Corp increased its stake in shares of Juno Therapeutics by 7.4% in the second quarter. State Street Corp now owns 3,236,384 shares of the biopharmaceutical company’s stock valued at $96,742,000 after buying an additional 222,754 shares during the period. Finally, Capital World Investors increased its stake in shares of Juno Therapeutics by 13.8% in the second quarter. Capital World Investors now owns 2,425,000 shares of the biopharmaceutical company’s stock valued at $72,483,000 after buying an additional 295,000 shares during the period. Institutional investors own 65.03% of the company’s stock.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.